

Results Update

Monday, 2 March 2009



enara TA One, 22 Jalan P Ramie 50250 Kuala Lumpur. Malaysia Tel : 603 - 2072 1277 Fax : 603 - 2032 5048

Analyst : TA Research

Tel : 20721277 ext : 1616
e-mail : ikmalhafizi@ta.com.my

KLCI : 889.7 Bloomberg : PHRM MK

Pharmaniaga Berhad

Results Within Target

Share Price: RM3.52
Target Price: RM3.95
Market Capitalisation: RM107mn

Board : Main Sector : Pharmaceutical

Recommendation : HOLD Stock code : 8133

Key Stock Statistics

		2007	2008	2009F		
EPS	(sen)	46.8	56.1	60.7		
P/E	(x)	7.5	6.3	5.8		
Div / Share	(sen)	18.0	11.9	18.2		
BV / Share	(sen)	3.4	3.6	4.2		
Issued Capital	(mn)	107				
52 weeks price	(%)	4.04 / 3.10				
Major shareholders	Khazanah - 86%					


Per Share Data

		2007	2008	2009F	2010F	
Book Value	(sen)	3.4	3.6	4.2	4.9	
Cash Flow	(sen)	- 1.2	35.0	122.3	180.9	
Earnings	(sen)	46.8	56.1	60.7	100.8	
Gross Dividend	(sen)	18.0	11.9	18.2	30.2	
Dividend Yield	(%)	5.1	3.4	5.2	8.6	
PER	(x)	7.5	0.1	5.8	3.5	
ROE	(%)	15.6	11.1	15.2	21.4	

P&L Analysis (RM mil)

	2007	2008	2009F	2010F	
Revenue	1184.0	1305.6	1482.8	1646.6	
Cost of Revenue	1080.8	1073.8	1366.8	1473.5	
EBITDA	103.2	101.5	115.9	173.0	
Net Interest	5.4	9.7	7.2	5.4	
Depreciation	21.6	21.9	22.3	22.7	
Net Profit	50.1	60.0	64.9	107.8	

Share Price chart



Source : Bloomberg

4Q08 Results Analysis

. 200 Hooding / manyone								
			Cumulative 4Q					
er	3Q08	4Q08	Q0Q%	FY07	FY08	YOY%		
	314.30	328.80	5%	1183.90	1305.60	10%		
	19.30	26.08	35%	87.56	96.86	11%		
(p)	-1.66	-1.59	-4%	-9.67	-6.27	-35%		
	17.64	24.49	39%	77.89	90.59	16%		
	-6.60	-6.57	0%	-26.18	-29.19	11%		
	10.59	17.80	68%	50.08	60.03	20%		
(sen)	9.90	16.60	68%	46.82	56.12	20%		
(%)	6.1%	7.9%		7.4%	7.4%			
(%)	5.6%	7.4%		6.6%	6.9%			
(%)	37.4%	26.8%		33.6%	32.2%			
	(sen) (%) (%)	er 3Q08 314.30 19.30 (p) -1.66 17.64 -6.60 10.59 (sen) 9.90 (%) 6.1% (%) 5.6%	er 3Q08 4Q08 314.30 328.80 19.30 26.08 319.30 26.08 31	er 3Q08 4Q08 QOQ% 314.30 328.80 5% 19.30 26.08 35% 17.66 -1.59 -4% 17.64 24.49 39% -6.60 -6.57 0% 10.59 17.80 68% (sen) 9.90 16.60 68% (%) 6.1% 7.9% (%) 5.6% 7.4%	Cumulative at 3Q08 4Q08 QOQ% FY07 314.30 328.80 5% 1183.90 19.30 26.08 35% 87.56 317.66 -1.59 -4% -9.67 17.64 24.49 39% 77.89 -6.60 -6.57 0% -26.18 10.59 17.80 68% 50.08 (sen) 9.90 16.60 68% 46.82 (%) 6.1% 7.9% 7.4% (%) 5.6% 7.4% 6.6%	Cumulative 4Q Ser 3Q08 4Q08 QOQ% FY07 FY08 314.30 328.80 5% 1183.90 1305.60 19.30 26.08 35% 87.56 96.86 3(p) -1.66 -1.59 -4% -9.67 -6.27 17.64 24.49 39% 77.89 90.59 -6.60 -6.57 0% -26.18 -29.19 (sen) 9.90 16.60 68% 50.08 60.03 (sen) 9.90 16.60 68% 46.82 56.12 (%) 6.1% 7.9% 7.4% 7.4% (%) 5.6% 7.4% 6.6% 6.9%		

Review

- Pharmaniaga's full year results saw the company reporting RM60.03mn in net profit or 56.12sen per share. The performance is backed by revenue of RM1.305bn.
- The results came well within our estimate of RM58mn in net income.
- Compared to 3Q08, the group's revenue rose by 5%. Net income outpaced revenue with 68% increment QoQ.
- The company managed to register sales growth of 10% YoY while net profit surged by 20% YoY. This is due to improved gross profit margin and the share of results of an associate.
- Margin during the year remained stable despite the tough economic condition, partly because the group was able to pass on some of the increase in costs to consumers.

Impact

At this juncture we are leaving our FY09 numbers intact. We believe the 1Q09 results announcement would provide better insights as to the viability of the company - before we make any adjustment to our projections.

Outlook

The company has asked for extension of its listing status as it is currently in breach of the minimum public shareholding spread requirement. This issue is still a big concern plaguing sentiment of its share trading activities.

Valuation

We maintain our target price at RM3.95 - based on a PER multiple of 6.5x. As the potential upside is still above 10% we maintain our HOLD call on the company.

Disclaimer

The information in this report has been obtained from sources believed to be reliable. Its accuracy or completeness is not guaranteed and opinions are subject to change without notice. This report is for information only and not to be construed as a solicitation for contracts. We accept no liability for any direct or indirect loss arising from the use of this document. We, our associates, directors, employees may have an interest in the securities and/or companies mentioned herein.

Other disclosure: CMDF-Bursa Research Scheme ("CBRS") - This report has been prepared by TA Securities Holdings Bhd for purposes of CBRS administered by Bursa Malaysia Berhad, independent from any influence from CBRS or the subject company. TA Securities Holdings Bhd has been compensated to undertake the scheme.

for TA SECURITIES HOLDINGS BERHAD(14948-M)

(A Participating Organisation of Bursa Malaysia Securities Berhad)

Yaw Chun Soon, Executive Director – Operations